Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

Launched by CASE COMPREHENSIVE CANCER CENTER · Apr 24, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at whether timed fasting—where you don't eat for certain hours each day—can be safely used by women with epithelial ovarian cancer who are undergoing chemotherapy before surgery. The researchers want to see if this fasting approach can help improve patients' quality of life, manage symptoms better, and lead to better treatment outcomes compared to following standard dietary advice. Essentially, they're trying to find out if fasting is doable, safe, and acceptable for patients during their chemotherapy treatments.

To participate, women must be at least 18 years old and have a confirmed diagnosis of epithelial ovarian cancer. They should be receiving or planning to start neoadjuvant chemotherapy, which is treatment given before surgery to shrink the tumor. If eligible, participants will follow either a fasting schedule—where they fast for 16 hours a day and eat normally for 8 hours—or standard dietary recommendations for 6 to 9 weeks before their surgery. Throughout the trial, all participants will undergo various assessments, including nutritional evaluations, blood tests, and surveys about their well-being. This study is currently recruiting eligible participants, so if you or someone you know fits the criteria, it might be an option to consider.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years and above
• • Participants with confirmed diagnosis of primary epithelial ovarian cancer (EOC) by internal cytologic or histologic evaluation (including fallopian tube and primary peritoneal cancer)
• • Participant who had undergone laparoscopic evaluation or laparotomy for diagnosis but did not proceed with surgical debulking
• • Participants with stage III or IV EOC planned to undergo chemotherapy including neoadjuvant chemotherapy
• • Participants with recurrent epithelial ovarian cancer who will receive platinum-based chemotherapy
• • Any invasive ovarian cancer histology
• • Normal cognitive function
• Exclusion Criteria:
• • Age \<18 years
• • Malignant complete or partial bowel obstruction confirmed on imaging.
• • Participants unable to provide informed consent.
• • BMI \<18
• • Participants diagnosed with severe malnutrition as assessed by study dietitian
• • Type I diabetes on insulin
• • Absence of pretreatment CT abdomen and pelvis imaging or \>4-6 weeks between imaging and cycle 1 of chemotherapy.